Skip to main content
IX BIOPHARMA LTD. logo

IX BIOPHARMA LTD. — Investor Relations & Filings

Ticker · 42C ISIN · SG1BD9000009 SGX Manufacturing
Open in API
Filings indexed 41 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country SG Singapore
Listing SGX 42C

About IX BIOPHARMA LTD.

https://www.ixbiopharma.com/

IX Biopharma Ltd. is a specialty pharmaceutical and nutraceutical company focused on developing and commercializing innovative therapies. Leveraging its proprietary WaferiX sublingual drug delivery technology, the company aims to improve the quality of life for patients with pain, chronic diseases, and debilitating conditions, particularly those affecting the central nervous system. A key product is Wafermine, a sublingual ketamine wafer designed for rapid, non-opioid relief of acute moderate to severe pain. The company was recently awarded a US$41 million U.S. government contract to fund Wafermine's Phase 3 clinical development and secure FDA Emergency Use Authorization. Additionally, iX Biopharma offers nutraceutical products, such as a sublingual NAD+ wafer for cellular energy production.

Recent filings

Filing Released Lang Actions
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Share Issue/Capital Change Classification · 98% confidence The document is an official Singapore Exchange announcement by the Board of Directors detailing the allotment and issuance of new ordinary shares pursuant to the exercise of warrants. It is specifically about increasing issued share capital rather than reporting results or providing financial statements. This fits the definition of a share issuance or capital change announcement. Therefore, it should be classified as a Share Issue/Capital Change (SHA).
2026-05-22 English
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Share Issue/Capital Change Classification · 91% confidence The document announces the allotment and issuance of new ordinary shares pursuant to the exercise of warrants, detailing the increase in issued share capital and outstanding warrants. This is a notification of a share issue/capital change, not a financial report or earnings release. It clearly falls under Share Issue/Capital Change (SHA).
2026-05-15 English
Equity Listing - Ordinary Shares::Issue and Allotment of New Shares Pursuant to iX Performance Share Plan
Share Issue/Capital Change Classification · 92% confidence The document is an official announcement by iX Biopharma Ltd. regarding the issue and allotment of 4,068,185 new shares under its Performance Share Plan. It provides details on the number of shares, vesting dates, share ranking, listing timetable, and post-issuance share count. This is a share issuance/capital change event rather than a financial report or earnings release, fitting the definition of Share Issue/Capital Change (SHA).
2026-05-13 English
Equity Listing - Ordinary Shares::Issuance and Allotment of Directors' Shares and Subscription Shares
Share Issue/Capital Change Classification · 92% confidence The document is an official announcement by iX Biopharma Ltd regarding the issuance and allotment of new shares (both directors’ shares and subscription shares) and the resulting change in the company’s total issued share capital. It is a corporate action involving share issuance rather than a regulatory filing, report publication, or insider trading report. This fits the “Share Issue/Capital Change” category.
2026-05-13 English
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Share Issue/Capital Change Classification · 87% confidence The document is an announcement that the company has issued and allotted new ordinary shares pursuant to the exercise of warrants, describing the number of new shares issued, the exercise price, updated share count, and outstanding warrants. This is a notice of a share issue/capital change. Therefore, it fits the “Share Issue/Capital Change” category (Code: SHA).
2026-05-12 English
Equity Listing - Ordinary Shares::Issue and Allotment of Shares Pursuant to Exercise of Warrants
Share Issue/Capital Change Classification · 90% confidence The document is a corporate announcement by iX Biopharma Ltd’s Board describing the allotment and issuance of new ordinary shares following the exercise of warrants. It details the number of shares issued, exercise price, outstanding warrants, and future listing date. This clearly constitutes a change in capital structure via new share issuance. The appropriate category is Share Issue/Capital Change (SHA).
2026-05-06 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.